Profile
Michael E.
Markels worked as a Senior Director in Marketing at Biogen, Inc. in 2006.
He also worked as a Senior Director in Infectious Disease & Oncology at InterMune, Inc. in 2002.
From 1990 to 2001, he worked at Glaxo Wellcome, Inc. as a Director in Global Commercial Strategy.
He was also a Senior VP in Commercial & Business Development at NeurogesX, Inc. Mr. Markels holds an MBA from Duke University and an undergraduate degree from Colorado State University.
Former positions of Michael E. Markels
Companies | Position | End |
---|---|---|
BIOGEN INC. | Sales & Marketing | 2006-04-30 |
INTERMUNE INC | Corporate Officer/Principal | 2002-09-30 |
Glaxo Wellcome, Inc. | Corporate Officer/Principal | 2000-12-31 |
NEUROGESX, INC | Corporate Officer/Principal | - |
Training of Michael E. Markels
Colorado State University | Undergraduate Degree |
Duke University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BIOGEN INC. | Health Technology |
Private companies | 3 |
---|---|
Glaxo Wellcome, Inc. | Health Technology |
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
NeurogesX, Inc.
NeurogesX, Inc. Pharmaceuticals: MajorHealth Technology NeurogesX, Inc. developed and commercialized novel pain management therapies. The company was founded by Wendye R. Robbins on May 28, 1998 and was headquartered in San Mateo, CA. | Health Technology |
- Stock Market
- Insiders
- Michael E. Markels